Press Release

Therapeutic Vaccines Market to grow with a CAGR of 9.68% through 2028

Increasing prevalence of various chronic ailments and increase in the geriatric population is expected to drive the Global Therapeutic Vaccines Market growth in the forecast period, 2024-2028.

According to TechSci Research report, Therapeutic Vaccines Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018–2028F”. Global Therapeutic Vaccines Market stood at USD 27.81 Billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 9.68% through 2028. Increased awareness of the potential value of vaccination in developed, developing, and underdeveloped regions is a key driver of the therapeutic vaccine market. Other factors contributing to market growth include government funding for vaccine development, the rising prevalence of diseases, and increased R&D expenditure by businesses. Governmental and humanitarian organizations have shown significant interest in disease prevention through vaccination, leading to the adoption of new products and strategies, and the formation of a donor market that accounts for the largest share of the global vaccine market. The global therapeutic vaccines market is driven by the rising incidence of chronic infectious diseases, cancer, Alzheimer's disease, and more.

Therapeutic vaccines are specifically manufactured for individuals who are HIV positive with a healthy immune system, aiming to enhance their ability to combat microorganisms. These vaccines are currently being developed for chronic viral infections like human immunodeficiency virus (HIV), human papillomavirus (HPV), herpes simplex virus (HSV), cancer, hepatitis B virus, and hepatitis C virus, as an alternative to antiviral treatment. The global therapeutic vaccines market is still in its early stages, with numerous players actively involved in the development of these vaccines. Some companies have implemented key business strategies, such as product innovation and new product launches, to establish their dominance in the global therapeutic vaccines market. The market is positively influenced by the significant increase in the prevalence of chronic diseases such as cancer and HIV. Several companies have taken a leading role in the research and development of therapeutic vaccines. For example, in April 2010, Dendreon Corporation launched Provenge, an FDA-approved immunotherapy drug for the treatment of prostate cancer. According to the U.S. Department of Health and Human Services, there are vaccines in the clinical trial stage, including Lucanix (Belagenpumatucel-L) and gp100 melanoma vaccine for non-small cell lung cancer. Likewise, Merck & Co., Inc. and GSK Plc. are expected to launch vaccines such as GSK1572932A and GV1001, which have entered phase 3 trials.

Cancer is the second leading cause of death worldwide, with approximately 9.6 million deaths in 2018. Around 70% of cancer deaths occur in low and middle-income countries. In 2018, there were 2.09 million lung cancer cases and 2.09 million breast cancer cases globally. Infections such as hepatitis and human papillomavirus (HPV) are responsible for up to 25% of cancer cases in low and middle-income countries. Therapeutic vaccines have the potential to address major disease populations, making them a significant factor in boosting the global therapeutic vaccines market. According to Alzheimer's Association, in 2006, there were 26.6 million cases of Alzheimer's disease worldwide, and it is predicted to reach 106.8 million cases by 2050. Tuberculosis (TB) remains a significant global health concern, with an estimated 1.5 million deaths in 2014.

The Joint United Nations Program on HIV/AIDS (UNAIDS) estimates that more than 40 million people are infected with HIV worldwide, with thousands of new infections each day. Government subsidies to pharmaceutical companies, particularly for health research, are expected to drive the therapeutic vaccines market. For example, the National Institutes of Health (NIH) in the US contributes approximately US$30.9 billion annually to health research. In Canada, the Canadian Institute of Health Research (CIHR) and the Industrial Research Assistance Program provide nearly US$0.76 billion to health research each year. The UK Research Council contributes US$888 million annually to health research, making significant contributions that impact the therapeutic vaccines market. As regulatory processes become stricter and more competitive, new products must demonstrate significant clinical benefits in terms of safety and efficacy compared to existing products. This leads to head-to-head comparisons between market-leading products and new applicants in late-stage pipelines. For instance, vaccine candidates for HIV-1 overseen by WHO's Product Development for Vaccines Advisory Committee (PDVAC) include ALVAX pox prime with a protein boost, MF59/HVTN 100, VRC-HIVADV014-00-VP, VRC-HIVADV054-00-VP/HVTN 084, all in phase II trials. The Tuberculosis Vaccine Initiative (TBVI) is actively working on the development of new vaccine candidates, such as VPM1002 SII, Max Planck, MIP Cadila Pharma, M. Vaccae Anhui Zhifei Longcom, in phase 3 trials.

However, the high capital expenditure required for vaccine development presents a challenge to market growth. Ineffective research and development, as well as reimbursement policies, are key factors that hinder market growth. Additionally, due to the market being in its early stages, stringent regulatory implications are anticipated to impede progress. However, considering the vaccine's potential in treating various chronic diseases, these obstacles are expected to diminish gradually.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Therapeutic Vaccines Market


The Global Therapeutic Vaccines Market is segmented into product, technology, type of therapy, route of administration, distribution channel, regional distribution, and company.

Based on the product, the autoimmune vaccine segment is projected to hold the largest market share in the global therapeutic vaccines market during the forecast period. The growing prevalence of manufacturing vaccines for various diseases to achieve significant results primarily drives the market's growth. Furthermore, the rising interest in innovative developments with the latest technologies increases the demand for targeted diseases, further propelling the segment's growth. Therapeutic vaccines have demonstrated high efficacy in treating diseases with minimal or no side effects, which contributes to the market's growth rate. The increasing support from private and public organizations for healthcare centers also plays a crucial role in driving the segment's growth.

Based on region, North America segment is expected to grow during the forecast period.  The North American region is anticipated to make a significant contribution to the market's growth during the study period. Factors such as the increasing cancer burden, rising research and development expenditures, and growing number of product launches are projected to drive market growth. For example, according to the data from the American Cancer Society for 2022, it is estimated that there will be 1.9 million new cancer cases diagnosed in the country, with approximately 236,740 new cases of lung cancer and 287,850 new cases of breast cancer. Additionally, the same source indicates that there will be 79,000 new cases of kidney cancer and 268,490 new cases of prostate cancer diagnosed in the country. These statistics highlight the significant burden of cancer among the population in the United States, which is expected to increase the demand for therapeutic vaccines for treatment and consequently drive market growth.

Major companies operating in Global Therapeutic Vaccines Market are:

  • Agenus Inc.
  • Argos Therapeutic Inc.
  • Celldex Therapeutic Inc. (Avant Immunotherapeutics, Inc.)
  • Dendreon Corp (Sanpower Group Co., Ltd.)
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Phio Pharmaceuticals Corp.
  • INOVIO Pharmaceuticals

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The increasing prevalence of various chronic ailments and the growing demand for effective biologic medications for targeted responses are key drivers of growth in the therapeutic vaccines market. Furthermore, the implementation of government initiatives promoting compulsory immunization during the COVID-19 pandemic, along with ongoing investments in biopharmaceutical companies for viral recombinants, are additional factors contributing to this growth. Moreover, the extensive utilization of morphogenesis gene therapy with exosome-mediated delivery technology for the development of patient-specific vaccines to address different cancer types is propelling market expansion. These advancements are complemented by the rising adoption of genetic engineering, the availability of expedited deployment vaccines, and the introduction of accelerated drug development solutions to enhance medicine designs. Additionally, rapid advancements in the healthcare sector, increased consumer awareness regarding access to various therapeutic drugs, and ongoing research and development (R&D) efforts to improve product effectiveness are fostering a positive outlook for the market.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

Therapeutic Vaccines Market Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product (Autoimmune Disease Vaccines, Neurological Disease Vaccines, Cancer Vaccines, Infectious Disease Vaccines, And Other Products), By Technology (Autologous Vaccines and Allogeneic Vaccines), By Type of Therapy (Monotherapy and Combination Therapy), By Route of Administration (Intravenous, Intradermal, Subcutaneous, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region and Competition”, has evaluated the future growth potential of Global Therapeutic Vaccines Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Therapeutic Vaccines Market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Web:  https://www.techsciresearch.com

Relevant News